Right Answer: â
The correct answer is C (VExUS Grade 3).
Explanation
⢠Prerequisite Met: The IVC is > 2cm (Plethoric) and non-collapsing, which allows for VExUS grading.
⢠Vein 1 (Hepatic): The presence of Systolic (S) Reversal constitutes a severe abnormality in the Hepatic Vein. * Vein 2 (Portal): A Pulsatility Index > 50% constitutes a severe abnormality in the Portal Vein.
⢠Grading Calculation: A VExUS Grade 3 is defined as an IVC > 2 cm plus severe abnormalities in 2 or more veins. * Clinical Implication: Even though the renal vein was not visualized, the presence of two other severe venous markers (Hepatic and Portal) confirms Grade 3. This indicates the heart cannot manage the current venous return, and the AKI is likely exacerbated by venous congestion (venous excess) rather than hypovolemia.
Modified VExUS
Modified VExUS (mVExUS) focuses more directly on venous Doppler abnormalities and can be particularly useful when the IVC is difficult to interpret or is not markedly dilated.
The commonly assessed venous Doppler patterns remain:
⢠Hepatic vein: systolic flow reversal â severe congestion
⢠Portal vein: pulsatility >50% â severe congestion
⢠Intrarenal vein: discontinuous/biphasic or monophasic flow â increasing severity of congestion
In the modified VExUS approach, venous Doppler abnormalities can be considered without making a plethoric IVC an absolute prerequisite, making it potentially more applicable in patients in whom IVC assessment is unreliableâfor example, those on mechanical ventilation, with altered intra-abdominal pressure, or with challenging echocardiographic windows.
ðNephroCC Pearl
ð¥ VExUS (Venous Excess Ultrasound Score) Grade 3, defined by a plethoric IVC (> 2 cm) plus severe flow abnormalities in two or more visceral veins (e.g., Hepatic Vein Reversal and Portal Pulsatility Index > 50%), signifies severe systemic venous congestion.
ð¥Clinical Implication: In a patient with oliguric AKI and equivocal physical exam, VExUS Grade 3 strongly suggests that the kidney injury is driven by congestive nephropathy (venous hypertension) rather than volume depletion. These finding mandates volume-removing strategies (diuretics/dialysis) rather than fluid administration.
ð¥Supporting Evidence & Development
The protocol was developed by a multidisciplinary team of experts in intensive care, nephrology, and cardiology (including Dr. Philippe Rola and Dr. William Beaubien-Souligny). Key milestones in the literature include:
⢠Original Validation: The 2020 study demonstrated that a VExUS Grade 3 had a specificity of 96% for predicting Acute Kidney Injury (AKI) in post-cardiac surgery patients.
⢠Heart Failure Applications: Recent prospective studies (e.g., Longino et al., 2025) and trials in emergency departments have shown that VExUS is superior to Central Venous Pressure (CVP) and physical exams for predicting heart failure readmissions and mortality.
⢠Expansion to General ICU: Meta-analyses (e.g., PubMed Central, 2025) have confirmed its utility in non-cardiac critically ill patients, specifically in managing "congestive nephropathy" where high venous pressureârather than low arterial flowâis the driver of kidney failure.